Literature DB >> 11108159

Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer.

N Takahashi1, Y Fujibayashi, Y Yonekura, M J Welch, A Waki, T Tsuchida, N Sadato, K Sugimoto, H Itoh.   

Abstract

62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) (62Cu-ATSM) has been proposed as a generator-produced, positron-emitting tracer for hypoxic tissue imaging. From basic studies, the retention mechanism of 62Cu-ATSM is considered to be closely related to cytosolic/microsomal bioreduction, a possible system for hypoxic bioreductive drug activation. In order to evaluate the characteristics of 62Cu-ATSM, PET studies were performed in 4 normal subjects and 6 patients with lung cancer. 62Cu-ATSM cleared rapidly from the blood with little lung uptake (0.43+/-0.09, uptake ratio; divided by the arterial input function) in normal subjects. Intense tumor uptake of 62Cu-ATSM was observed in all patients with lung cancer (3.00+/-1.50). A negative correlation was observed between blood flow and flow-normalized 62Cu-ATSM uptake in three of four patients. In contrast, 62Cu-ATSM uptake was not related to that of 18F-fluorodeoxyglucose. The negative correlation between blood flow and flow normalized 62Cu-ATSM uptake suggests an enhancement of retention of 62Cu-ATSM by low flow. 62Cu-ATSM is a promising PET tracer for tumor imaging, which might bring new information for chemotherapeutic treatment as well as radiotherapy of hypoxic tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108159     DOI: 10.1007/bf02988690

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  30 in total

Review 1.  Positron emission tomography (PET): expanding the horizons of oncology drug development.

Authors:  Lisa A Hammond; Louis Denis; Umber Salman; Paul Jerabek; Charles R Thomas; John G Kuhn
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

2.  Feasibility of 62Cu-ATSM PET for evaluation of brain ischaemia and misery perfusion in patients with cerebrovascular disease.

Authors:  Makoto Isozaki; Yasushi Kiyono; Yoshikazu Arai; Takashi Kudo; Tetsuya Mori; Rikiya Maruyama; Ken-ichiro Kikuta; Hidehiko Okazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-02       Impact factor: 9.236

3.  A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.

Authors:  Chad N Hancock; Luke H Stockwin; Bingnan Han; Raymond D Divelbiss; Jung Ho Jun; Sanjay V Malhotra; Melinda G Hollingshead; Dianne L Newton
Journal:  Free Radic Biol Med       Date:  2010-11-04       Impact factor: 7.376

4.  Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.

Authors:  Sibaprasad Bhattacharyya; Manish Dixit
Journal:  Dalton Trans       Date:  2011-05-03       Impact factor: 4.390

5.  Copper-64 Radiopharmaceuticals for Oncologic Imaging.

Authors:  Jason P Holland; Riccardo Ferdani; Carolyn J Anderson; Jason S Lewis
Journal:  PET Clin       Date:  2009-01

Review 6.  The development of copper radiopharmaceuticals for imaging and therapy.

Authors:  Monica Shokeen; Thaddeus J Wadas
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

Review 7.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

8.  Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research.

Authors:  Carolyn J Anderson; Riccardo Ferdani
Journal:  Cancer Biother Radiopharm       Date:  2009-08       Impact factor: 3.099

Review 9.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

10.  In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Authors:  Farrokh Dehdashti; Mark A Mintun; Jason S Lewis; Jeffrey Bradley; Ramaswamy Govindan; Richard Laforest; Michael J Welch; Barry A Siegel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.